Previous 10 | Next 10 |
Noteworthy events during the week of March 17 - 23 for healthcare investors. More news on: SCYNEXIS, Inc., Sage Therapeutics, Inc., Intrexon Corporation, Healthcare stocks news, , Read more ...
SALT LAKE CITY , March 14, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that it has been selected to present LPCN 1144 clinical results as part of ENDO 2019. The presentation will highlight the therapeutic potential of...
Nano cap Conatus Pharmaceuticals ( CNAT +22.2% ) is up on more than a 4x surge in volume. Shares have rallied 43% this week. More news on: Conatus Pharmaceuticals Inc., Madrigal Pharmaceuticals, Inc., Viking Therapeutics, Inc., Healthcare stocks news, Stocks on the move, ...
Bio-Path Holdings (NASDAQ: BPTH ) +32% . More news on: Bio-Path Holdings, Inc., Stitch Fix, Inc., Akebia Therapeutics, Inc., Stocks on the move, Read more ...
Nano cap Lipocine (NASDAQ: LPCN ) is up 29% premarket on increased volume in response to positive 16-week result s from an open-label liver fat imaging study of NASH candidate LPCN 1144. More news on: Lipocine Inc., Healthcare stocks news, Stocks on the move, Read more ......
SALT LAKE CITY , March 12, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on endocrine and metabolic disorders, today announced top-line results from the 16-week Liver Fat Imaging Study ("Liver Fat Study") with LPCN 1144. Pr...
SALT LAKE CITY , March 11, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that Morgan Brown , Executive Vice President and Chief Financial Officer, will provide a corporate overview to investors at the 31 st Annual RO...
Lipocine (NASDAQ: LPCN ): FY GAAP EPS of -$0.55. More news on: Lipocine Inc., Earnings news and commentary, , Read more ...
SALT LAKE CITY , March 6, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced financial results for the year ended December 31, 2018 . Fourth Quarter 2019 and Recent Corporate Highlights Currently conducting an ABPM cl...
The FDA has signed off on Lipocine's ( LPCN -7.6% ) IND for a Phase 2 clinical trial assessing LPCN 1144 in patients with nonalcoholic steatohepatitis (NASH) with fibrosis. Participants in the randomized study will be treated for 36 weeks. More news on: Lipocine Inc., Healthcare stocks...
News, Short Squeeze, Breakout and More Instantly...
2024-07-27 02:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study PR Newswire Met standard bioequivalence (BE) criteria C max, AUC 0-t , and AUC 0- ∞ C trough criterion was met LPCN 1154 was well tolerat...
Shares of Lipocine Inc. (NASDAQ: LPCN) traded at a new 52-week high today and are currently trading at $8.96. So far today, approximately 78,318 shares have been exchanged, as compared to an average 30-day volume of 32,701 shares. Lipocine Inc., a clinical-stage biopharmaceutical company, foc...